Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Clinical Significance of Interstitial Pneumonia with Autoimmune Features in Cryptogenic Organizing Pneumonia: A Prospective Multicenter Observational Study.
Higo H, Ichikawa H, Arakawa Y, Mori Y, Tamura T, Kuyama S, Matsumoto C, Sugimoto K, Hamada N, Suwaki T, Itano J, Tanimoto Y, Senoo S, Taniguchi A, Inukai Y, Arita M, Makimoto S, Kojima K, Matsushita T, Maeda Y, Miyahara N. Higo H, et al. Among authors: kuyama s. J Clin Med. 2024 Nov 15;13(22):6870. doi: 10.3390/jcm13226870. J Clin Med. 2024. PMID: 39598014 Free PMC article.
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.
Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, Danchaivijitr P, Han JY, Sun JM, Sugawara S, Pan E, Ren N, Chen A, Rajagopalan R, Lisberg AE. Okamoto I, et al. Among authors: kuyama s. Future Oncol. 2024;20(37):2927-2936. doi: 10.1080/14796694.2024.2409621. Epub 2024 Oct 29. Future Oncol. 2024. PMID: 39469838 Free PMC article. Clinical Trial.
Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study.
Masuda T, Tsubata Y, Hata K, Horie M, Kiura K, Kanaji N, Inoue T, Kodani M, Yanai M, Yamaguchi K, Matsumoto N, Yamasaki M, Ishikawa N, Masuda K, Takigawa N, Kuyama S, Kubota T, Nishii K, Hotta K, Hattori N. Masuda T, et al. Among authors: kuyama s. Thorac Cancer. 2024 Dec;15(34):2408-2417. doi: 10.1111/1759-7714.15469. Epub 2024 Oct 16. Thorac Cancer. 2024. PMID: 39415454 Free PMC article.
Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status.
Nakashima K, Kodama H, Murakami H, Takahashi T, Kawakado K, Yanagawa T, Kitani K, Hottta T, Abe M, Hamai K, Tanimoto T, Ishikawa N, Tamura T, Kuyama S, Isobe T, Tsubata Y. Nakashima K, et al. Among authors: kuyama s. Respir Investig. 2024 Nov;62(6):1137-1141. doi: 10.1016/j.resinv.2024.09.010. Epub 2024 Oct 3. Respir Investig. 2024. PMID: 39366122 Free article.
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Goksu SS, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S; ADRIATIC Investigators. Cheng Y, et al. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. N Engl J Med. 2024. PMID: 39268857 Clinical Trial.
A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: The OLCSG2101 study protocol.
Nakamura N, Makimoto G, Tanaka T, Kato Y, Oze I, Kozuki T, Yokoyama T, Ichikawa H, Kuyama S, Hara N, Maeda Y, Hotta K. Nakamura N, et al. Among authors: kuyama s. Respir Investig. 2024 Sep;62(5):897-900. doi: 10.1016/j.resinv.2024.07.017. Epub 2024 Aug 7. Respir Investig. 2024. PMID: 39182943
105 results